PTAB institutes Bass' Tecfidera IPR

The Patent Trial and Appeal Board instituted an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging a patent covering multiple sclerosis drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB).

PTAB determined that Bass' group has a reasonable likelihood of demonstrating the patent's claims are unpatentable. A final decision from PTAB is due within a year. ...